Bessemer Group
HZNP

Bessemer Group’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Bessemer Group’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-42
Closed -$4K – 2332
2023
Q3 		$4K Sell
42
-1,140
-96% -$122K ﹤0.01% 1825
2023
Q2 		$122K Hold
1,182
– – ﹤0.01% 1175
2023
Q1 		$129K Sell
1,182
-414
-26% -$45.8K ﹤0.01% 1006
2022
Q4 		$182K Buy
1,596
+7
+0.4% +$581 ﹤0.01% 914
2022
Q3 		$98K Buy
1,589
+250
+19% +$17.5K ﹤0.01% 1035
2022
Q2 		$107K Sell
1,339
-5
-0.4% -$473 ﹤0.01% 1004
2022
Q1 		$141K Buy
1,344
+5
+0.4% +$487 ﹤0.01% 902
2021
Q4 		$144K Buy
1,339
+1,076
+409% +$117K ﹤0.01% 926
2021
Q3 		$29K Buy
263
+76
+41% +$7.89K ﹤0.01% 1163
2021
Q2 		$18K Hold
187
– – ﹤0.01% 1253
2021
Q1 		$17K Buy
187
+92
+97% +$7.76K ﹤0.01% 1213
2020
Q4 		$7K Sell
95
-1,074,417
-100% -$79.9M ﹤0.01% 1347
2020
Q3 		$83.5M Buy
+1,074,512
New +$73.9M 0.25% 110
2019
Q4 		– Sell
-367
Closed -$10K – 1851
2019
Q3 		$10K Buy
+367
New +$9.49K ﹤0.01% 1485
2019
Q2 		– Sell
-91
Closed -$2.31K – 1915
2019
Q1 		$2K Buy
+91
New +$2.16K ﹤0.01% 1703
2015
Q4 		– Sell
-64,341
Closed -$1.27M – 1795
2015
Q3 		$1.27M Buy
+64,341
New +$2.03M 0.01% 516

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.05B AUM 19.75% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Bessemer Group's HZNP Position: Q4 2023 in Review

Bessemer Group sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 42 shares — an estimated $4K sold.

Bessemer Group first reported a position in HZNP in Q3 2015 and held it in 16 quarters. The position peaked at $83.5M in Q3 2020. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Bessemer Group reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Bessemer Group sold 42 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $4K.
  • Bessemer Group first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2015 and held it in 16 quarters.
  • Bessemer Group's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $83.5M in Q3 2020.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Bessemer Group's 13F filing for Q4 2023, filed 9 Feb 2024.